Oilfield services firm Core Laboratories' Q4 revenue rises

Reuters
02/05
Oilfield services firm <a href="https://laohu8.com/S/CLB">Core Laboratories</a>' Q4 revenue rises

Overview

  • Oilfield services firm's Q4 revenue rose 7% yr/yr

  • Company repurchased 363,207 shares for $5.7 mln

Outlook

  • Core Laboratories projects Q1 2026 revenue between $124 mln and $130 mln

  • Company expects Q1 2026 EPS to be $0.11 to $0.15

Result Drivers

  • INTERNATIONAL DEMAND - Strong international demand for proprietary technologies drove revenue growth, with significant contributions from unconventional reservoir rock testing in the Middle East

  • REGIONAL STUDY SALES - Increased sales of regional studies in Africa and Brazil contributed to revenue, reflecting renewed exploration interest

  • OFFSHORE PROJECT - Successful completion of an offshore project using PAC™ technology reduced costs and execution time, contributing positively to results

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$138.30 mln

$131.10 mln (2 Analysts)

Q4 EPS

$0.15

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy."

  • Wall Street's median 12-month price target for Core Laboratories Inc is $14.00, about 28.6% below its February 4 closing price of $19.61

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nPn9XqwM2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10